Wednesday, September 06, 2023
XtalPi and Parthenon Therapeutics have announced a collaboration aimed at the discovery of innovative therapeutic antibodies for the treatment of solid tumours.
Under this agreement, XtalPi will grant Parthenon Therapeutics access to its cutting-edge XupremAb™ antibody discovery platform. This platform represents a comprehensive suite of solutions that seamlessly integrate artificial intelligence (AI) and wet lab techniques. The result is the rapid identification of therapeutic antibody candidates boasting exceptional efficacy and developability profiles.
Parthenon Therapeutics and XtalPi will use different methods within the XupremAb™ platform to better explore the immune system. This collaboration represents a promising step towards improving the lives of cancer patients through innovative and effective therapies.
This collaboration harnesses the power of a proprietary platform at the forefront of technological advancement. Its primary objective is to conduct an in-depth exploration of the immune repertoire, ultimately leading to the discovery of state-of-the-art antibody therapeutics.
Combined with Parthenon's extensive expertise in biotherapeutic drug discovery, including invaluable insights into the intricacies of the tumour microenvironment and mechanisms responsible for immune exclusion, this partnership is poised to pave the way for transformative cancer therapies.
